Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.91 USD
Change Today +0.63 / 4.41%
Volume 1.8M
FOLD On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (FOLD) Key Developments

Amicus Therapeutics, Inc., Scioderm, LLC - M&A Call

To discuss the agreement under which Amicus will acquire 100% of the capital stock of Scioderm, Inc

Amicus Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Financial Guidance for the Full Year of 2015

Amicus Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $26,943,000, net loss of $27,133,000 or $0.27 per basic and diluted share against loss from operations of $14,266,000, net loss of $14,614,000 or $0.22 per basic and diluted share a year ago. The wider net loss is primarily attributed to an increase in operating expenses. For the six months, the company reported loss from operations of $51,001,000, net loss of $51,421,000 or $0.53 per basic and diluted share against loss from operations of $29,887,000, net loss of $30,557,000 or $0.46 per basic and diluted share a year ago. The company continues to expect full-year 2015 net cash spend between $100 million and $110 million. The current cash position is projected to fund operations into 2017.

Amicus Therapeutics, Inc. to Report Q2, 2015 Results on Aug 05, 2015

Amicus Therapeutics, Inc. announced that they will report Q2, 2015 results on Aug 05, 2015

Amicus Therapeutics, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Amicus Therapeutics, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Amicus Therapeutics, Inc.(NasdaqGM:FOLD) added to Russell 2000 Index

Amicus Therapeutics, Inc. will be added to Russell 2000 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $14.91 USD +0.63

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies
 

Industry Analysis

FOLD

Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4,873.4x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4,547.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.